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Infectious bronchitis virus (IBV) 3b protein is highly conserved among group 3 coronaviruses, suggesting that it is important for infection. A
previous report (Virology 2003, 311:16–27) indicated that transfected IBV 3b localized to the nucleus in mammalian cells using a vaccinia-virus
expression system. Although we confirmed these findings, we observed cytoplasmic localization of IBV 3b with apparent exclusion from the
nucleus in avian cells (IBV normally infects chickens). IBV 3b was virtually undetectable by microscopy in mammalian cells transfected without
vaccinia virus and in IBV-infected mammalian cells because of a greatly reduced half-life in these cells. A proteasome inhibitor stabilized IBV 3b
in mammalian cells, but had little effect on IBV 3b in avian cells, suggesting that rapid turnover of IBV 3b in mammalian cells is proteasome-
dependent while turnover in avian cells may be proteasome-independent. Our results highlight the importance of using cells derived from the
natural host when studying coronavirus non-structural proteins.
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Members of the Coronaviridae family have large, positive-
sense, single stranded RNA genomes (reviewed in Navas-
Martin and Weiss, 2004). During infection, four structural
proteins are expressed: spike (S), membrane (M), nucleocapsid
(N), and envelope (E). Interestingly, several other open reading
frames (ORFs) between the structural protein ORFs produce
proteins of undetermined function during infection (Brown and
Brierley, 1995). These proteins are thought to be non-structural,
accessory proteins that are essential for productive viral
infection in the natural host, but dispensable for virus growth
in cell culture. For example, recombinant infectious bronchitis
virus (IBV) lacking the IBV 5a gene showed similar cytopathic
effect (CPE), and growth kinetics when compared to wild-type
virus in cell culture, although final titers were slightly lower
(Youn et al., 2005). Another group reported comparable results
for the IBV 5b gene (Casais et al., 2005). A recent study
showed the emergence of a mutant IBV following 36 passages0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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IBV 3b (Shen et al., 2003). This result indicated that full-length
IBV 3b is not essential for virus replication in Vero cells.
Infectious clones of murine hepatitis virus (MHV) lacking the
MHV 2a gene and/or the MHV 4 and MHV 5a genes showed
CPE and growth kinetics that mirrored wild-type virus in
cultured cells, although final titers were 10-fold lower in virus
lacking the MHV 4 and MHV 5a genes (de Haan et al., 2002).
Significantly, MHV lacking these genes showed attenuated
infection in the natural host. Similar attenuation of infection by
deletion of coronavirus accessory proteins has been reported
for feline infectious peritonitis virus (Haijema et al., 2004) and
transmissible gastroenteritis virus (Curtis et al., 2002; Ortego
et al., 2003; Sola et al., 2003). Recently, more attention has
been paid to coronavirus accessory proteins following the
implication of a newly discovered coronavirus as a human
pathogen in severe acute respiratory syndrome (SARS)
(reviewed in Tan et al., 2005). Study of these accessory
proteins will help more fully elucidate pathogenesis mechan-
isms and may lead to the development of more effective
antiviral drugs.
IBV, a group 3 coronavirus, produces two non-structural
proteins, 3a and 3b, from ORFs located between the S and E6) 337 – 345
www.e
Fig. 1. Anti-IBV 3b antibodies are specific for IBV 3b. In vitro transcription
translation was performed using pBS (empty vector) and pBS/IBV 3b
Transcription/translation reactions were immunoprecipitated with anti-IBV 3b
antibodies and visualized via SDS-PAGE. Input from the reaction that was no
immunoprecipitated was used as a positive control.
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from subgenomic mRNA 3, with IBV 3a translation initiated
via the first AUG, and the downstream IBV 3b translation
initiated via leaky ribosomal scanning (Liu and Inglis, 1992).
Subgenomic mRNA 3 also produces the IBV E protein through
an internal ribosomal entry site. The amino acid sequences of
the IBV 3a and IBV 3b proteins are highly conserved (81 to
86.2% similarity for IBV 3a and 87.5 to 95.4% for IBV 3b)
among group 3 field isolates from different continents and
decades (Jia and Naqi, 1997), suggesting that these proteins are
essential for infection of the natural host. We have been
studying the cell biology of the IBV 3a and 3b proteins to
understand their functions. Previously, we reported that a pool
of IBV 3a is tightly associated with membranes (Pendleton and
Machamer, 2005). This membrane-associated pool of IBV 3a
was localized in puncta at a novel domain of the smooth
endoplasmic reticulum, suggesting that it may modulate
cellular events occurring in this location. Another group
recently reported that transiently expressed, full-length IBV
3b is localized to the nucleus in mammalian cells infected with
vaccinia virus, while a C-terminally truncated form localized to
the both the cytoplasm and the nucleus (Shen et al., 2003). This
report was the first showing a non-essential, non-structural
coronavirus protein localized to the nucleus. Additionally,
recent reports have demonstrated that SARS 3b, which shares
no homology with IBV 3b but is translated from the same
genomic region, localizes to the nucleus when transiently
expressed (Yuan et al., in press).
Here, we confirm that IBV 3b localizes to the nucleus when
transiently expressed in vaccinia virus-infected mammalian
cells. However, our findings show that the localization of IBV
3b in IBV-infected avian cells is cytoplasmic with apparent
exclusion from the nucleus. Transient expression of IBV 3b
without the use of vaccinia virus gave a similar cytoplasmic
localization pattern in avian cells. Interestingly, IBV 3b protein
expression was significantly lower in all mammalian cells
tested when compared to avian cells. This reduction resulted
from increased turnover of IBV 3b in mammalian cells that was
mediated by the proteasome without the ubiquitylation of the
sole lysine residue in IBV 3b. In contrast, the turnover of IBV
3b in avian cells was unaffected by a proteasome inhibitor,
suggesting that it may be proteasome-independent. These
results have implications for the study of non-structural
coronavirus proteins, emphasizing the importance of using
cells derived from the natural host when studying coronavirus
accessory proteins.
Results
IBV 3b localization in mammalian and avian cells
IBV 3b is a small protein (63 amino acids) with no
predicted structural motifs or domains. Glutathione S-trans-
ferase (GST) protein fused to the N-terminus of IBV 3b was
expressed in bacteria, purified, and used to generate poly-
clonal antibodies to IBV 3b. Immunoprecipitation of in vitro
translated IBV 3b was used to screen the antisera. FollowingSDS-PAGE, a clear band at approximately 6 kDa
corresponding to in vitro translated IBV 3b was observed in
samples immunoprecipitated with anti-IBV 3b antibodies (Fig.
1). No band was seen when in vitro translation reactions using
an empty vector as template were immunoprecipitated. These
results indicated that the antibodies were specific for IBV 3b
(see also Fig. 3A).
Next, these antibodies were used to examine the intracel-
lular localization of IBV 3b. Vero cells were infected with
vTF7-3 (vaccinia virus expressing T7 RNA polymerase)
followed by transfection at 1 h postinfection (p.i.) with a
plasmid encoding IBV 3b driven by the T7 promoter. Analysis
by indirect immunofluorescence microscopy at 6 h p.i.
demonstrated that IBV 3b was localized mainly to the nucleus
(Fig. 2A). Non-transfected cells on the same coverslip served
as negative controls for antibody staining. Similar results were
obtained in BHK-21 and HeLa cells (not shown). These
findings are consistent with earlier studies (Shen et al., 2003).
However, Vero cells transiently transfected without the use of
vTF7-3 using a plasmid encoding IBV 3b expressed from the
human cytomegalovirus immediate early promoter showed
almost no IBV 3b staining (Fig. 2B). Inclusion of a plasmid
encoding the green fluorescent protein (GFP) during transfec-
tion marked the transfected cells. In the very few cells that did
show IBV 3b staining (approximately one cell per 100,000),
variable localization patterns were seen. Interestingly, none of
these cells showed the mainly nuclear localization pattern that
was observed in vaccinia virus-infected cells. Similar results
were seen in HeLa and COS-7 cells (not shown). Importantly,
transiently transfected GFP was readily expressed in these cells/
.
t
Fig. 2. IBV 3b localization in transiently transfected Vero cells. (A) vTF7-3-
infected Vero cells were transiently transfected with pBS/IBV 3b at 1 h p.i.
Cells were fixed and stained for indirect immunofluorescence at 6 h p.i. using
anti-IBV 3b and anti-protein disulfide isomerase (PDI) antibodies. Scale bar, 15
Am. (B) Vero cells were transiently co-transfected with pEGFP-N1 (GFP-
expressing vector) and pCMV/IBV 3b using Fugene 6. At 24 h posttransfection,
cells were fixed and stained for indirect immunofluorescence with anti-IBV 3b
and mouse anti-GFP antibodies.
A.R. Pendleton, C.E. Machamer / Virology 345 (2006) 337–345 339(12.5% transfection efficiency) indicating that the lack of IBV
3b expression was not due to poor transfection. Transient
transfection with a plasmid encoding tagged IBV 3b (pCMV/
IBV 3b + G) followed by indirect immunofluorescence staining
with antibodies to the G protein tag also showed virtually no
IBV 3b staining (not shown). Therefore, the lack of IBV 3b
staining did not result from a conformation or modification of
IBV 3b that precluded recognition by anti-IBV 3b polyclonal
antibodies. Finally, IBV 3b expression was undetectable in
IBV-infected Vero cells by indirect immunofluorescence
microscopy (not shown).Fig. 3. IBV 3b localization in avian cells. (A) DF1 cells were infected with IBV (I)
visualized by immunoblotting using anti-IBV 3b antibodies. The figure shows one g
transfected with the pEGFP-N1 (GFP-expressing vector) and pCMV/IBV 3b plasm
indirect immunofluorescence with anti-IBV 3b and mouse anti-GFP antibodies. Sca
and stained for indirect immunofluorescence at 24 h p.i. using anti-IBV 3b and anBecause in vitro translated IBV 3b was readily detected by
immunoprecipitation with anti-IBV 3b antibodies (Fig. 1), we
hypothesized that the lack of IBV 3b expression by indirect
immunofluorescence microscopy might be due to reduced IBV
3b protein levels in mammalian cells. Therefore, the presence
of IBV 3b was assessed in cells derived from chickens, the
natural IBV host. A clear band of the appropriate size for IBV
3b (approximately 6 kDa) was seen by immunoblotting of
lysates from infected avian DF1 cells, but not mock-infected
cells, again confirming IBV 3b antibody specificity (Fig. 3A).
Additionally, transient transfection of DF1 cells with plasmids
encoding IBV 3b and GFP (13.3% transfection efficiency)
showed strong IBV 3b expression by indirect immunofluores-
cence microscopy. Intriguingly, IBV 3b was localized to the
cytoplasm in these cells and appeared to be excluded from the
nucleus (Fig. 3B), although more analytical techniques might
be needed to definitively conclude that no IBV 3b is present in
the nucleus. A similar IBV 3b localization pattern was
observed in IBV-infected primary chicken embryo fibroblasts
(CEFs) (Fig. 3C), IBV-infected DF1 cells (not shown), and
DF1 cells transiently expressing a tagged version of IBV 3b
(not shown). Thus, in contrast to results in mammalian cells,
IBV 3b is readily visualized by indirect immunofluorescence
microscopy in avian-derived cells.
IBV 3b is turned over more rapidly in Vero cells than in avian
DF1 cells
To analyze the reduced IBV 3b expression in IBV-infected
and plasmid-transfected mammalian cells, the half-life of IBV
3b was compared in mammalian and avian cells. IBV-infected
Vero and DF1 cells were labeled with [35S]-methionine–
cysteine for 30 min. Cells were either harvested immediately (0
min chase time) or incubated in growth media for 15, 30, 45, or
60 min. Samples were divided in half with each half being
immunoprecipitated by either anti-IBV 3b antibodies or anti-or mock-infected (M) as a negative control for 24 h. Cells were then lysed and
el with both lanes at the same exposure level. (B) DF1 cells were transiently co-
ids. At approximately 24 h posttransfection, cells were fixed and stained for
le bar, 10 Am. (C) IBV-infected primary chicken embryo fibroblasts were fixed
ti-IBV E antibodies. Scale bar, 15 Am.
Fig. 4. IBV 3b is rapidly degraded in Vero cells. (A) IBV-infected DF1 or Vero
cells were labeled at 24 h p.i. (DF1) or 12 h p.i. (Vero) for 30 min with [35S]-
methionine–cysteine followed by incubation in growth media for the chase
times indicated. ‘‘M’’ denotes mock-infected cells. Samples were immunopre-
cipitated with anti-IBV 3b or anti-IBV 3a antibodies. (B) For each chase time,
the graph shows the percent of original label seen at the 0 min chase that is
remaining. Half-life calculations represent the average T standard deviation of
at least 3 experiments.
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Quantitation of SDS-PAGE gels from three experiments
indicated that the half-life of IBV 3b was 60 min T 6 min in
DF1 cells while the half-life in Vero cells was 7.5 min (Fig.
4B). Half-life analysis of IBV 3b in DF1 and Vero cells
transiently transfected with plasmids encoding IBV 3b gave
similar results (not shown). Importantly, transient expression of
a tagged version of IBV 3b (IBV 3b + G) followed by
immunoprecipitation with antibodies to the protein tag also
showed similar turnover rates in DF1 and Vero cells (not
shown). These results confirmed that IBV 3b was not
alternatively modified in Vero cells such that it became
inaccessible to anti-IBV 3b antibodies. Thus, increased
turnover of IBV 3b appeared to be responsible for its decreased
expression in mammalian cells.
The turnover of IBV 3b is partially proteasome-dependent in
Vero cells
To further assess the impact of turnover rates on IBV 3b
expression in mammalian cells, Vero cells transiently trans-
fected with plasmids encoding IBV 3b and GFP were treated
for 4 h with the cell-permeable proteasome inhibitor, MG132,
or DMSO as a control. During the final 25 min of MG132
treatment, cells were incubated in methionine–cysteine-free
media (TMG132) for 15 min followed by labeling with [35S]-
methionine–cysteine (T MG132) for 10 min. Cells were then
harvested and samples were split in half, with each half beingimmunoprecipitated with either anti-GFP antibodies (a control
for transfection efficiency, not shown) or anti-IBV 3b
antibodies. Results demonstrated a marked increase of IBV
3b levels in MG132-treated Vero cells, indicating proteasome
involvement in the rapid rate of turnover of IBV 3b in Vero
cells (Fig. 5A, lanes 1–4). IBV 3b expression was also
readily detected by indirect immunofluorescence microscopy
throughout the nucleus and cytoplasm under these same
conditions (Fig. 5D). Surprisingly, treatment with MG132 did
not cause significant accumulation of IBV 3b in DF1 cells
(Fig. 5A, lanes 1–4). Also, the amount of IBV 3b remaining
after a 60 min chase in the presence of MG132 was only
marginally increased in DF1 cells (Fig. 5C, lanes 3–4). The
level of ubiquitylated-actin was increased in MG132-treated
DF1 cells, which served as a positive control (Fig. 5B).
Interestingly, the amount of IBV 3b remaining after a 60 min
chase in MG132-treated Vero cells (Fig. 5C, lanes 3–4) was
similar to that seen in DF1cells (both treated and untreated)
(Fig. 5C, lanes 1–4). These results suggest that a proteasome-
independent mechanism may be primarily responsible for the
degradation of IBV 3b in DF1 cells, and that a similar
degradation method could be responsible for IBV 3b turnover
in MG132-treated Vero cells.
Proteins are typically targeted for degradation via poly-
ubiquitylation of lysine residues in the target protein. We
mutated the single lysine residue in IBV 3b (Beaudette strain)
to arginine (IBV 3b K17R) to test the contribution of this lysine
to IBV 3b turnover. Expression (Fig. 5A, lanes 5–7) and
localization (not shown) of IBV 3b K17R in DF1 cells were
similar to the wild-type protein. Vero cells were transiently
transfected with plasmids encoding IBV 3b and GFP or IBV 3b
K17R and GFP. Cells were incubated in methionine–cysteine-
free media for 15 min followed by labeling in [35S]-
methionine–cysteine for 10 min. Samples were split in half
and each half was immunoprecipitated with either anti-GFP
antibodies (transfection control, not shown) or anti-IBV 3b
antibodies. IBV 3b K17R was not stabilized relative to wild-
type IBV 3b in Vero cells (Fig. 5A, lanes 5–7), indicating that
the proteasome-mediated turnover of IBV 3b in mammalian
cells did not depend on ubiquitylation of the IBV 3b lysine
residue.
Discussion
IBV 3b is a highly conserved protein among group 3
coronaviruses (Jia and Naqi, 1997), suggesting it has a critical
function in viral infection. Mammalian cells, particularly Vero
cells, are frequently used to study IBV at the cellular level.
However, our results have demonstrated significant differ-
ences in IBV 3b localization and turnover in mammalian cells
when compared to avian cells. In chickens, IBV normally
infects tracheal, bronchial, bursa, kidney, and chorioallentoic
membrane epithelial cells, depending on the virus strain
(Kapczynski et al., 2002; Naqi, 1990; Yagyu and Ohta, 1990).
The mammalian cell lines used in this study were derived
from either epithelial or fibroblast cells. The levels of
expression and localization patterns in mammalian cells of
Fig. 5. Increased turnover of IBV 3b inVero cells is mediated by the proteasome. (A) Vero andDF1 cells were transiently transfectedwith a total of 2 Ag ofDNAmade up
of one of the following combinations of plasmids: (a) pEGFP-N1 (GFP-expressing vector) and pCMV/IBV 3b (labeled ‘‘3b’’), (b) pEGFP-N1 and pCMV/IBV 3b K17R
(labeled ‘‘K17R’’), or (c) pEGFP-N1 alone (labeled ‘‘V’’). At 24 h posttransfection, cells were treatedwith either (i) 50 AMMG132 (in DMSO) for 4 h, (ii) DMSO for 4 h,
or (iii) no treatment. For the final 25min ofMG132 treatment, cells were incubated in serum-freemedium lackingmethionine and cysteine (TMG132/DMSO) for 15min
followed by labeling with [35S]-methionine–cysteine (TMG132/DMSO) for 10 min. Samples were then immunoprecipitated with anti-IBV 3b antibodies or anti-GFP
antibodies (not shown). The figure shows a single gel in which the lanes containing Vero cells have been transformed (using Quantity One software) so that the signal
intensity shown is about 40 times more than the intensity shown in the DF1 cell lanes. * Denotes a background band. (B) Mock-transfected DF1 cells were treated with
MG132 (labeled ‘‘+’’) or DMSO alone (labeled ‘‘’’) without radiolabeling. Cells were then lysed and immunoprecipitated with anti-actin antibodies. Following SDS-
PAGE, samples were immunoblotted with anti-ubiquitin antibodies and visualized by enhanced chemiluminescence. (C) Vero andDF1 cells were transiently transfected
with pCMV/IBV 3b. At 24 h posttransfection, cells were radiolabeled and treated with MG132 or DMSO as described in panel A for 4 h. Cells were then incubated in
regular growth medium (TMG132) for the chase times indicated. Immunoprecipitation with anti-IBV 3b antibodies followed. (D) Vero cells were transiently co-
transfected with pEGFP-N1 and pCMV/IBV 3b. At 24 h posttransfection, cells were treated with MG132 for 4 h and fixed and stained for indirect immunofluorescence
using anti-IBV 3b and anti-GFP antibodies. Scale bar, 15 Am.
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Therefore, our results may point toward species specific
differences in IBV 3b protein localization and turnover,
suggesting that the study of this protein may be best
accomplished in avian-derived cells.
One of the substantial differences observed in IBV 3b
protein expression between avian and mammalian cells was
that degradation of IBV 3b occurred much more rapidly in
mammalian cells, resulting in almost undetectable levels of the
protein by microscopy. This increased turnover of IBV 3b in
mammalian cells (Fig. 4) was shown to be mediated by the
proteasome while a proteasome-independent mechanism might
be primarily responsible for the turnover of IBV 3b in avian
cells (Fig. 5A). Interestingly, treatment of Vero cells with
MG132 did not completely stabilize IBV 3b, but rather
reduced its turnover rate to that found in avian cells. This
result suggests that a proteasome-independent mechanism of
turnover might be functional in both mammalian and avian
cells, but that an additional proteasome-mediated degradation
pathway for IBV 3b causes its extremely rapid turnover in
Vero cells.
Proteasome-independent degradation has been described for
several cytoplasmic proteins, including origin recognition
complex 1B (ORC1B) protein, a DNA replication protein
(Miyake et al., 2005), and InBa, a specific inhibitor of NFnB
(Shumway and Miyamoto, 2004). In the case of InBa, acytoplasmic protein that is constitutively and rapidly degraded
by a proteasome-independent mechanism in certain B-lympho-
cytes, degradation was shown to be through the action of
calcium/calmodulin-dependent proteases. An analogous mech-
anism through these or other proteases might function in
proteasome-independent degradation of IBV 3b.
Intriguingly, when examining the additional proteasome-
mediated turnover mechanism that is functional in Vero cells,
we made the surprising discovery that mutating the one lysine
in IBV 3b to arginine did not stabilize IBV 3b (Fig. 5A, lanes
5–7). Proteasome-dependent protein degradation is thought to
occur primarily through the covalent addition of polyubiquitin
to a lysine residue within the protein to be degraded. However,
exceptions have been reported (reviewed in Ciechanover and
Ben-Saadon, 2004; Hoyt and Coffino, 2004). For example,
several proteins, including human papillomavirus and Epstein–
Barr virus proteins, are polyubiquitylated at the amino-
terminus (Aviel et al., 2000; Ikeda et al., 2002; Kuo et al.,
2004; Reinstein et al., 2000). Also, a recent report showed that
in cells infected with Kaposi’s sarcoma-associated herpesvirus,
a viral protein was able to polyubiquitylate cysteine residues of
a cellular transmembrane protein, leading to degradation
through the lysosomal pathway (Cadwell and Coscoy, 2005).
For other proteins, such as the cell-cycle regulatory protein
p21Cip1, proteasomal degradation has been shown to be
independent of ubiquitin addition; however, the specific
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Chen et al., 2004; Sheaff et al., 2000). Also, ornithine
decarboxylase (Zhang et al., 2003) and cyclin D1 (Newman
et al., 2004) are targeted for proteasomal degradation by the
non-covalent binding of antizyme, a protein that is recognized
by the same domain of the proteasome that recognizes
polyubiquitin. Any of these potential mechanisms might
explain the observed proteasomal degradation of IBV 3b in
mammalian cells that is independent of ubiquitin addition at
Lys17. The differences between avian and mammalian pro-
teomes might allow recognition of IBV 3b by antizyme or the
N-terminal ubiquitylation machinery in mammalian cells but
not avian cells. Or, alternative posttranslational modification of
IBV 3b in mammalian cells might cause these effects.
Although SDS-PAGE did not show any differences in the
electrophoretic mobility of IBV 3b in avian versus mammalian
cells, more sensitive analytical methods might be needed to
detect such differences. Additionally, IBV 3b may be protected
from degradation by binding to a specific protein partner in
avian cells that it is unable to bind in mammalian cells because
of sequence differences or different posttranslation modifica-
tions. Given the small size of IBV 3b (¨6 kDa) that would
allow it to freely diffuse into the nucleus, the possible
cytoplasmic retention of IBV 3b (Figs. 3B and C) suggests
that such a scenario may be possible.
Interestingly, the increased turnover rate of IBV 3b might
also explain the altered localization pattern of IBV 3b in
vaccinia virus-infected mammalian cells when compared to
transiently transfected or IBV-infected avian cells. Vaccinia
virus infection of mammalian cells resulted in the localization
of IBV 3b mainly to the nucleus (Fig. 2A). However, in avian
cells, IBV 3b was localized to the cytoplasm with what may be
nuclear exclusion (Figs. 3B and C). Additionally, in non-vTF7-
3-infected Vero cells, IBV 3b was localized throughout the
cytoplasm and nucleus upon treatment of cells with a
proteasome inhibitor (Fig. 5D). Interestingly, one study
indicated that proteasome-mediated, ubiquitin-independent
turnover of p21Cip1 was contingent on its localization:
nuclear-localized p21Cip1 was rapidly degraded while cyto-
plasmic p21Cip1 was stable (Sheaff et al., 2000). Conversely,
another cell-cycle regulatory protein, p27 Kip1, was stabilized in
the nucleus while being quickly degraded when localized to the
cytoplasm (Tomoda et al., 1999). Potentially, IBV 3b could be
protected from degradation in the mammalian nucleus. This
protection in conjunction with the massive amounts of IBV 3b
produced by the robust vaccinia virus expression system might
result in primarily nuclear IBV 3b in Vero cells if enough IBV
3b were able to reach the nucleus before being degraded.
Alternatively, vaccinia virus infection might directly alter
proteasome degradation of nuclear proteins or IBV 3b
localization. Regardless, the vaccinia virus transfection system
results in IBV 3b expression that is dissimilar to the more
physiologically relevant expression found in IBV-infected
avian and mammalian cells. Additionally, the lack of nuclear
enrichment of IBV 3b during infection suggests that functional
similarities between IBV 3b and nuclear localized SARS 3b are
unlikely.Finally, the differences in turnover of IBV 3b in mammalian
versus avian cells have implications for functional and genetic
studies of IBV 3b. One group recently reported the emergence
of a C-terminally truncated version of IBV 3b following 36
passages in Vero cells (Shen et al., 2003). This study showed
that full-length IBV 3b was not essential for virus replication in
Vero cells, but did not rule out the possibility of an essential
function for the N-terminus of the protein. However, the
extremely short half-life of IBV 3b in Vero cells indicates that
it is unlikely that any portion of IBV 3b is essential for viral
replication in mammalian cell culture. Future studies using an
infectious clone lacking IBV 3b will determine if IBV 3b is
also dispensable for virus replication in avian cells. Finally, the
IBV 3b protein in some strains of IBV lacks lysines. However,
the proteasome-mediated degradation of IBV 3b in mammalian
cells is not dependent on lysine ubiquitylation, suggesting that
IBV 3b from any strain of IBV would need to be studied in
avian systems. The results presented here document significant
differences in localization and turnover of the IBV 3b
accessory protein in different cell culture systems, thus
suggesting the importance of using cells derived from the
natural host when studying coronavirus accessory proteins.
Materials and methods
Cells and viruses
HeLa (human cervical epithelial), BHK-21 (baby hamster
kidney fibroblast), COS7 (African green monkey kidney
fibroblast-like), and UMNSAH/DF1 (DF1) (immortalized
chicken embryo fibroblast) cells were maintained in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Life Technologies, Carlsbad, CA) supplemented
with 10% fetal calf serum (Atlanta Biologicals, Norcross, GA)
and 0.1 mg/ml Normocin (Invivogen, San Diego, CA). Vero
(African green monkey kidney epithelial) cells were main-
tained in DMEM supplemented with 5% fetal calf serum and
Normocin. Primary chicken embryo fibroblasts (CEF) were a
gift from Dr. K. Beemon (Johns Hopkins University, Balti-
more, MD). Fibroblasts were maintained in Media 199
(Invitrogen) supplemented with 1% heat-inactivated chicken
serum (Invitrogen), 1% fetal bovine serum (Invitrogen), and
2% tryptose phosphate (Sigma–Aldrich Co., St. Louis, MO).
The previously described Vero-adapted Beaudette strain of IBV
(Machamer and Rose, 1987) was used in all experiments with
IBV-infected Vero cells. The egg-adapted strain of IBV
(American Type Tissue Culture VR-22) was used in all
experiments with IBV-infected DF1 cells and CEF cells. A
vaccinia virus encoding T7 RNA polymerase (vTF7-3) was
obtained from Bernard Moss (National Institutes of Health,
Bethesda, MD) (Fuerst et al., 1986).
Plasmids
The IBV 3b gene was cloned by reverse transcription-PCR
of mRNA isolated from IBV-infected Vero cells as described
previously (Pendleton and Machamer, 2005). Briefly, primers
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IBV 3b and a BamHI restriction site behind the stop codon of
IBV 3b were used to amplify the IBV 3b gene. These two
restriction sites were then used to clone IBV 3b into pBluescript
SK (pBS) (Stratagene, La Jolla, CA) behind the T7 promoter.
Dideoxy sequencing confirmed that the IBV 3b sequence in this
construct (called pBS/IBV 3b) matched the known IBV 3b
Beaudette strain sequence (Liu et al., 1991). PCR amplification
of pBS/IBV 3b with the same EcoRI-containing 5V primer and a
3V primer containing a NotI restriction site was performed to
clone IBV 3b in frame with the C-terminal tail of the vesicular
stomatitis virus G (VSV-G) protein (The C-terminal tail of the
VSV-G protein had previously been inserted into the pBS
plasmid using RT-PCR). This plasmid was named pBS/IBV
3b + G. IBV 3b + G was then subcloned into the pEGFP-N1
plasmid (BD Biosciences Clontech, San Diego, CA) using the
EcoRI and XbaI restriction sites. A stop codon followed the
IBV 3b + G reading frame so that the GFP protein was not
expressed. This plasmid was named pCMV/IBV 3b + G. A
plasmid encoding IBV 3b with the lysine17 codon mutated to
that for arginine was generated using QuikChange mutagenesis
(Stratagene, La Jolla, CA) on the pBS/IBV 3b plasmid
according to the manufacturer’s protocol. The resulting plasmid
was named pBS/IBV 3b K17R. pBS/IBV 3b and pBS/IBV 3b
K17R were used to subclone IBV 3b and IBV 3b K17R into the
pEGFP-N1 plasmid with the EcoRI and BamHI restriction
enzymes. Again, stop codons were located at the end of the
IBV 3b and IBV 3b K17R ORFs. Thus, GFP was not expressed
from these plasmids. These plasmids were named pCMV/IBV
3b and pCMV/IBV 3b K17R. PCR amplification was performed
on the pBS/IBV 3b plasmid with primers containing BamHI
(5V) and EcoRI (3V) sites to clone IBV 3b into pGEX-2T
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ). The
resulting plasmid, which contained the glutathione S-transfer-
ase (GST) protein fused to the N-terminus of IBV 3b, was
named pGEX-2T/IBV 3b.
Fusion protein expression
The GST Gene Fusion System (Amersham) was used to
express and purify the GST-IBV 3b fusion protein. Briefly,
BL21 Escherichia coli bacteria were transformed with either
the pGEX-2T/IBV 3b plasmid or pGEX-2T. Individual
bacterial colonies were picked and grown overnight in YT
broth (0.8% BactoTryptone (BD Biosciences, San Diego, CA),
1% Bacto yeast extract (BD Biosciences), 0.5% NaCl (Sigma))
containing 80 Ag/ml ampicillin (Sigma). The next day, cultures
were diluted 1:10 and grown to an OD600 of approximately 0.6.
GST-IBV 3b and GST protein expression was then induced by
growing cultures in 0.1 mM (final concentration) isopropyl-h-
d-thiogalactopyranoside (Amersham) for 2 days at 13.5 -C.
Cultures were pelleted by centrifugation at 20,800  g for 1
min and resuspended in phosphate-buffered saline (Sigma) plus
protease inhibitors (Sigma, catalog number P8340). Following
sonication and pelleting of the cellular debris, soluble protein
was bound to Glutathione Sepharose 4B (Amersham) overnight
at 4 -C. Beads were then washed three times with PBS plusprotease inhibitors at 4 -C followed by elution (two times) of
protein at 4 -C in a solution containing 10 mM reduced
glutathione (Sigma) and 50 mM Tris–HCl (Sigma) [pH 8].
SDS-PAGE analysis combined with Coomassie staining was
used to assess purity and yield of GST-IBV 3b.
Antibodies
Purified GST-IBV 3b protein was used to create polyclonal
antibodies in rabbits (Covance Research Products Inc., Denver,
PA). Initially, the ability of anti-IBV 3b antibodies to recognize
the IBV 3b protein was assessed using an in vitro TNT quick
coupled transcription/translation T7 system (Promega Corpo-
ration, Madison, WI) according to the manufacturer’s protocol.
Briefly, pBS (empty vector) or pBS/IBV 3b was incubated for
90 min at 30 -C in a transcription/translation master mix
containing [35S]-Redivue–methionine (Amersham). Samples
were then diluted in a detergent solution containing 62.5 mM
EDTA (J.T. Baker, Phillipsburg, NJ), 50 mM Tris–HCl [pH 8],
0.4% deoxycholic acid (CalBiochem, La Jolla, CA), and 1%
nonidet P40 substitute (Fluka Chemie AG, Buchs, Switzerland)
plus protease inhibitors and immunoprecipitated with anti-IBV
3b antibodies. Immunoprecipitations were analyzed by SDS-
PAGE and fluorography. Input from the in vitro translated
reaction that had not been immunoprecipitated was used as a
positive control.
Mouse anti-GFP antibodies used in indirect immunofluores-
cence microscopy were from Roche Molecular Biochemicals
(Indianapolis, IN). Rabbit anti-GFP antibodies used in immu-
noprecipitation assays and Alexa-488-conjugated donkey anti-
mouse immunoglobulin (IgG) were fromMolecular Probes, Inc.
(Eugene, OR). Texas red-conjugated donkey anti-rabbit IgGwas
obtained from Jackson ImmunoResearch Laboratories, Inc.
(West Grove, PA). Mouse anti-protein disulfide isomerase
antibodies, which label the endoplasmic reticulum, were from
Stressgen Biotechnologies, Inc. (San Diego, CA). The rat
polyclonal anti-IBV E antibodywas described previously (Corse
and Machamer, 2000). Rabbit polyclonal antibodies to the C-
terminus of the vesicular stomatitis virus G protein were also
described previously (Swift and Machamer, 1991). Mouse anti-
actin antibodies were from ICN Biomedicals, Inc. (Aurora,
OH). Affinity-purified rabbit anti-ubiquitin antibodies were a
generous gift from Dr. Cecile Pickart (Johns Hopkins
University School of Public Health, Baltimore, MD).
Infection and transient transfection
IBV infection was performed at a multiplicity of infection
(MOI) of ¨1 by allowing virus to absorb to cells in a small
volume of serum-free DMEM for 1 h at 37 -C. Cells were then
transferred to DMEM supplemented with 2% fetal calf serum
and antibiotics. Infection with vTF7-3 was performed as
previously described (Corse and Machamer, 2000) in serum-
free DMEM. At 1 h postinfection (p.i.), vTF7-3-infected cells
were transfected with 2 Ag DNA per 35-mm dish and 6 Al of
Fugene 6 (Roche) for 5 h. Transient transfection was performed
by adding 2 Ag DNA per 35-mm dish for approximately 24
A.R. Pendleton, C.E. Machamer / Virology 345 (2006) 337–345344h with 6 Al of Fugene 6. Plasmid-based transient transfection
was performed without the use of vaccinia virus unless
otherwise specified.
Indirect immunofluorescence microscopy
The method used for indirect immunofluorescence micros-
copy has been described previously (Corse and Machamer,
2000). Briefly, cells were fixed with 3% paraformaldehyde
(Sigma) in phosphate-buffered saline for 10 min at room
temperature. Permeabilization with 0.5% Triton X-100 (Sigma)
for 3 min at room temperature followed. Cells were then
stained with the appropriate primary and secondary antibodies.
Images were taken on an Axioskop microscope (Zeiss, Thorn-
wood, NY) at a magnification of 630 with an attached Sensys
charge-coupled device camera (Photomerics, Tucson, AZ). IP
Lab imaging software (Signal Analystics, Vienna, VA) was
used to visualize images.
Immunoprecipitation and proteasome inhibitor treatment
Cells transiently transfected with pEGFP-N1 and either
pCMV/IBV 3b or pCMV/IBV 3b K17R were incubated in
serum-free media that lacked methionine and cysteine (Invitro-
gen) for 15 min before being labeled in [35S]-methionine–
cysteine (Promix; Amersham) for 10 min. Cells were then
harvested in a detergent solution plus protease inhibitors
(described above) and immunoprecipitated as previously
described (Machamer and Rose, 1987). Quantitation of [35S]-
labeled protein was done by exposing SDS-PAGE gels to a K-
HD imaging screen (Bio-Rad Laboratories, Hercules, CA)
followed by scanning with personal molecular imager FX (Bio-
Rad). Pixel intensity was determined with Quantity One
software (Bio-Rad).
Half-lives of the IBV 3b or IBV 3b + G proteins were
determined in infected or transiently transfected cells labeled
with [35S]-methionine–cysteine for 30 min. Cells were then
either harvested immediately (0 min chase time) in detergent
solution or incubated in normal growth medium for chase times
of 15, 30, 45, or 60 min. Mock-infected cells were harvested
immediately after labeling. Samples were immunoprecipitated
and analyzed by SDS-PAGE and quantitated as described
above. Half-lives were calculated by determining the formula
(in the form y = Aebx) for the best-fit exponential curve when
chase time (x) was graphed against pixel intensity ( y). The
half-life was equal to the x value when y was one-half the pixel
intensity of the 0 min chase time.
For proteasome inhibitor treatment, transiently transfected
cells were treated at approximately 24 h posttransfection with
50 AM MG132 (Sigma) for 4 h. During the final 25 min of
treatment, cells were incubated in serum-free medium lacking
methionine and cysteine (TMG132) for 15 min followed by
labeling with [35S]-methionine–cysteine (TMG132) for 10
min. Cells were then either harvested immediately or incubated
with normal growth medium (TMG132) for 60 min. As a
control, transfected cells were incubated in the same amount of
DMSO solvent as the MG132-treated cells. Cell lysates werethen immunoprecipitated, analyzed by SDS-PAGE, and quan-
titated as described above.
Immunoblotting
DF1 cells were infected for 24 h with IBVat a MOI of¨1 or
mock-infected as a negative control. Cells were lysed in a
solution containing 4% sodium dodecyl sulfate, 30% glycerol,
1% bromophenol blue, 10% 2-mercaptoethanol, and 0.1 M
Tris–HCl (pH 8). Samples were then run on 17.5% SDS-PAGE
gel and immunoblotted as described previously (Pendleton and
Machamer, 2005). As a positive control for the efficacy of
MG132 treatment in DF1 cells, mock-transfected cells were
treated with MG132 for 4 h. Cells were then lysed without
being radiolabeled and immunoprecipitated with anti-actin
antibodies. Following SDS-PAGE, samples were immuno-
blotted with anti-ubiquitin antibodies.
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